Kyntra Bio Inc (KYNB) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Kyntra Bio Inc   (NASDAQ: KYNB)

Select the Financial Report: Select the Period:


Description of Kyntra Bio Inc's Business Segments


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Composition of Kyntra Bio Inc Revenues by Segments
 
Drug Product Revenue Net    93.42 % of total Revenue
Drug Product Revenue Net Astellas Agreement    93.63 % of total Revenue
Drug Product Revenue Net Astellas Agreement Japan    -58.61 % of total Revenue
Drug Product Revenue Net Astellas Agreement Europe    152.03 % of total Revenue
Europe Astellas Europe Agreement    88.28 % of total Revenue
Drug Product Revenue Net Europe Astellas Agreement    152.03 % of total Revenue
Drug Product Revenue Net Japan Astellas Agreement    -58.61 % of total Revenue
Drug Product Revenue Net API Shipment    58.86 % of total Revenue
Bulk Drug Product Astellas Europe Agreement    165.86 % of total Revenue
Bulk Drug Product Europe Astellas Europe Agreement    13.38 % of total Revenue
Bulk Drug Product Europe Astellas Europe Agreement Royalty Revenue    40.13 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)		 %
(of total Revenues)
Drug Product Revenue Net 3.49 93.42 %
Drug Product Revenue Net Astellas Agreement 3.50 93.63 %
Drug Product Revenue Net Astellas Agreement Japan -2.19 -58.61 %
Drug Product Revenue Net Astellas Agreement Europe 5.68 152.03 %
Europe Astellas Europe Agreement 3.30 88.28 %
Drug Product Revenue Net Europe Astellas Agreement 5.68 152.03 %
Drug Product Revenue Net Japan Astellas Agreement -2.19 -58.61 %
Drug Product Revenue Net API Shipment 2.20 58.86 %
Bulk Drug Product Astellas Europe Agreement 6.20 165.86 %
Bulk Drug Product Europe Astellas Europe Agreement 0.50 13.38 %
Bulk Drug Product Europe Astellas Europe Agreement Royalty Revenue 1.50 40.13 %
Total 3.74 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%		 Q/Q Revenue
%
Drug Product Revenue Net 34.57 % -
Drug Product Revenue Net Astellas Agreement 34.62 % -
Drug Product Revenue Net Astellas Agreement Japan - -
Drug Product Revenue Net Astellas Agreement Europe 598.16 % -
Europe Astellas Europe Agreement - -
Drug Product Revenue Net Europe Astellas Agreement 598.16 % -
Drug Product Revenue Net Japan Astellas Agreement - -
Drug Product Revenue Net API Shipment 22.22 % -
Bulk Drug Product Astellas Europe Agreement - -
Bulk Drug Product Europe Astellas Europe Agreement - -
Bulk Drug Product Europe Astellas Europe Agreement Royalty Revenue 87.5 % -
Total - -41.96 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)		 %
(Profit Margin)
Total -15.20 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%		 Q/Q Income
%
Total - -




Annual Report on Kyntra Bio Inc Divisions, Sales by Country

 
Drug Product Revenue Net   Drug Product Revenue Net Segment contribution to total sales 90.81 % of total Revenue
Drug Product Revenue Net Astellas Agreement   Drug Product Revenue Net Astellas Agreement Segment contribution to total sales 90.06 % of total Revenue
Drug Product Revenue Net Astellas Agreement Japan   Drug Product Revenue Net Astellas Agreement Japan Segment contribution to total sales 12.31 % of total Revenue
Drug Product Revenue Net Astellas Agreement Europe   Drug Product Revenue Net Astellas Agreement Europe Segment contribution to total sales 78.49 % of total Revenue
AstraZeneca Agreements   AstraZeneca Agreements Segment contribution to total sales 3394.41 % of total Revenue
Europe   Europe Segment contribution to total sales 87.62 % of total Revenue
Japan   Japan Segment contribution to total sales 12.38 % of total Revenue


Twelve months ended 2025
KYNB s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
Drug Product Revenue Net 5.85 90.81 %
Drug Product Revenue Net Astellas Agreement 5.80 90.06 %
Drug Product Revenue Net Astellas Agreement Japan 0.79 12.31 %
Drug Product Revenue Net Astellas Agreement Europe 5.06 78.49 %
Total 6.44 100 %
AstraZeneca Agreements 218.60 3394.41 %
Europe 5.64 87.62 %
Japan 0.80 12.38 %


Twelve months ended 2025
KYNB s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
Total 183.45 2848.63 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Drug Product Revenue Net -78.87 % -
Drug Product Revenue Net Astellas Agreement 190 % -
Drug Product Revenue Net Astellas Agreement Japan - -
Drug Product Revenue Net Astellas Agreement Europe 3.71 % -
AstraZeneca Agreements 37.48 % -
Europe -10 % -
Japan - -
Drug Product Revenue Net AstraZeneca Agreements U S - -
United States - -
China - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.